Table 2 Hospital procedures, therapies, and discharge medications in acute heart failure patients with or without ACS
|  | Overall n = 2609 | ACS-AHF n = 725 (27.79 %) | NACS-ACS n = 1884 (72.21) | P value |
|---|---|---|---|---|
Hospital procedures and therapies | ||||
 IV nitroglycerine, n (%) | 725 (27.8) | 397 (54.8) | 328 (17.4) | <0.001 |
 Dopamine, n (%) | 468 (17.9) | 156 (21.5) | 312 (16.6) | 0.003 |
 Invasive ventilation (%) | 289 (11.1) | 106 (14.6) | 183 (9.7) | <0.001 |
 IABP, n (%) | 86 (3.3) | 57 (7.9) | 29 (1.5) | <0.001 |
 Cardiac pacing, n (%) | 36 (1.38) | 18 (2.48) | 18 (0.96) | 0.003 |
 Hospital ICD, n (%) | 150 (5.75) | 32 (4.41) | 118 (6.26) | 0.069 |
 Hospital CRT, n (%) | 68 (2.61) | 9 (1.24) | 59 (3.13) | 0.007 |
 CAG performed, n (%) | 764 (29.3) | 338 (46.6) | 426 (22.6) | <0.001 |
 Normal coronaries, n (%) | 183 (24.0) | 9 (2.7) | 174 (40.9) | <0.001 |
 Non-significant CAD | 82 (10.7) | 14 (4.1) | 68 (16.0) | <0.001 |
 Single-vessel CAD, n (%) | 105 (13.7) | 56 (16.6) | 49 (11.5) | 0.043 |
 Double-vessel CAD, n (%) | 116 (15.2) | 77 (22.8) | 39 (9.2) | <0.001 |
 LM or three-vessel CAD, n (%) | 263 (34.4) | 179 (53.0) | 84 (19.7) | <0.001 |
Discharge medications | ||||
 Aspirin, n (%) | 1989 (76.2) | 633 (87.3) | 1356 (72.0) | <0.001 |
 Warfarin, n (%) | 484 (18.5) | 56 (7.7) | 428 (22.7) | <0.001 |
 Statin, n (%) | 1813 (69.5) | 605 (83.4) | 1208 (64.1) | <0.001 |
 Lasix, n (%) | 2048 (78.5) | 546 (75.3) | 1502 (79.7) | 0.014 |
 Metolazone, n (%) | 115 (4.4) | 17 (2.3) | 98 (5.2) | 0.001 |
 Hydralazine, n (%) | 300 (11.5) | 61 (8.4) | 239 (12.7) | 0.002 |
 Long-acting nitrates, n (%) | 252 (9.7) | 103 (14.2) | 149 (7.9) | <0.001 |
 Amiodarone, n (%) | 75 (2.9) | 14 (1.9) | 61 (3.2) | 0.074 |
 Βeta-blockers, n (%) | 2180 (83.0) | 635 (87.6) | 1545 (82.0) | <0.001 |
 ACEI, n (%) | 1554 (59.6) | 463 (63.9) | 1091 (57.9) | 0.006 |
 ARBI, n (%) | 388 (14.9) | 95 (13.1) | 293 (15.5) | 0.115 |
 AA, n (%) | 999 (38.4) | 191 (26.3) | 808 (42.9) | <0.001 |